Table 3.
Total number of chemosensitive miRNAs when considering administration of specific chemotherapeutic agents in combination with variable administration of surgery and radiation, as evidenced by prolonged disease-specific survival. The miRNAs which produced a significant stratification in the SEER population samples in addition to significance on one or more measures in the NCI-60, MRRCC, CWRU, TCGA, and CCLE are in bold.
| Treatment | Cisplatin | Carboplatin | Paclitaxel | Etoposide | Any Chemotherapy |
|---|---|---|---|---|---|
| Surgery | miR-29b (miR-29b-1, miR-29b-2) |
miR-134, miR-142-3p (miR-142), miR-188, miR-380-5p (miR-380) |
miR-134, miR-138 (miR-138-2), miR-142-3p (miR-142), miR-188, miR-380-5p (miR-380) |
- |
miR-142-3p (miR-142), miR-433 |
| Radiation | - | - | miR-154, miR-302a* |
miR-141, miR-17-3p (miR-17), miR-17-5p (miR-17), miR-182, miR-183, miR-19b (miR-19b-1), miR-200c, miR-222, miR-23b |
miR-134 |
| Surgery And Radiation |
- |
miR-134, miR-142-3p (miR-142) |
miR-142-3p, miR-220 |
- | miR-142-3p (miR-142) |
| Any treatment |
miR-129 (miR-129-1, miR-129-2), miR-134, miR-142-3p (miR-142), miR-184, miR-198, miR-370, miR-373, miR-379 |
miR-134, miR-142-3p (miR-142), miR-206, miR-33 (miR-33-a), miR-370, miR-372 |
miR-134, miR-142-3p (miR-142), miR-199b, miR-370, miR-382 |
miR-129 (miR-129-1, miR-129-2), miR-141, miR-142-3p (miR-142), miR-184, miR-218 (miR-218-1), miR-220, miR-335, miR-373, miR-96 |
miR-33 (miR-33-a), miR-453, miR-372, miR-142-3p (miR-142), mir-299-3p, miR-329 (miR-329-2), miR-520d*, miR-519a, miR-494, miR-433, miR-134, miR-485-5p (miR-485), miR-518c*, miR-493-3p |